Abstract
We discuss possible gene therapies for the treatment of ischemic diseases in the central nervous system (CNS). These therapies aim at the prevention of carotid artery restenosis, stimulation of angiogenesis for ischemic brain, protection of neurons against ischemia, and prevention of vasospasm due to subarachnoid hemorrhage (SAH). Carotid artery restenosis can perhaps be approached by preventing vascular smooth muscle cell proliferation via gene therapy in addition to surgical treatment. Cerebral angiogenesis therapy might be applicable to moyamoya disease. Gene therapies with VEGF and HGF to stimulate angiogenesis have been successful in muscle, however, efficacy in the CNS is unknown. Gene transfection efficiency of viral vectors has been poor in the CNS, and the safety of such vectors is questionable. Therefore, development of gene therapy is for neural protection and prevention of vasospasm due to SAH has been limited. Infusion of HVJ-AVE liposomes into monkey cerebrospinal fluid (CSF) space yielded wide-spread gene transfection. HVJ-AVE liposomes may be a promising vector for use in the human CNS. Few currently available gene therapies appear to be options for clinical treatment of cerebral ischemia despite many experimental designs. In addition to the inherent difficulties of treating the CNS, vectors and methods for introducing vectors into the CNS must be improved.
Keywords: ischemic brain disease, gene therapy, hvj-ave, subarachinoid, subarachinoid hemorrhage
Current Gene Therapy
Title: Gene Therapy for Ischemic Brain Diseases
Volume: 3 Issue: 1
Author(s): Youichi Saitoh, Amami Kato, Yasushi Hagihara, Yasufumi Kaneda and Toshiki Yoshimine
Affiliation:
Keywords: ischemic brain disease, gene therapy, hvj-ave, subarachinoid, subarachinoid hemorrhage
Abstract: We discuss possible gene therapies for the treatment of ischemic diseases in the central nervous system (CNS). These therapies aim at the prevention of carotid artery restenosis, stimulation of angiogenesis for ischemic brain, protection of neurons against ischemia, and prevention of vasospasm due to subarachnoid hemorrhage (SAH). Carotid artery restenosis can perhaps be approached by preventing vascular smooth muscle cell proliferation via gene therapy in addition to surgical treatment. Cerebral angiogenesis therapy might be applicable to moyamoya disease. Gene therapies with VEGF and HGF to stimulate angiogenesis have been successful in muscle, however, efficacy in the CNS is unknown. Gene transfection efficiency of viral vectors has been poor in the CNS, and the safety of such vectors is questionable. Therefore, development of gene therapy is for neural protection and prevention of vasospasm due to SAH has been limited. Infusion of HVJ-AVE liposomes into monkey cerebrospinal fluid (CSF) space yielded wide-spread gene transfection. HVJ-AVE liposomes may be a promising vector for use in the human CNS. Few currently available gene therapies appear to be options for clinical treatment of cerebral ischemia despite many experimental designs. In addition to the inherent difficulties of treating the CNS, vectors and methods for introducing vectors into the CNS must be improved.
Export Options
About this article
Cite this article as:
Saitoh Youichi, Kato Amami, Hagihara Yasushi, Kaneda Yasufumi and Yoshimine Toshiki, Gene Therapy for Ischemic Brain Diseases, Current Gene Therapy 2003; 3 (1) . https://dx.doi.org/10.2174/1566523033347561
DOI https://dx.doi.org/10.2174/1566523033347561 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeting IGF-I, IGFBPs and IGF-I Receptor System in Cancer: The Current and Future in Breast Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery RNAi Applications in Therapy Development for Neurodegenerative Disease
Current Pharmaceutical Design Role of Transforming Growth Factor Beta in Corneal Function, Biology and Pathology
Current Molecular Medicine Targeted Liposomal Drug Delivery in Cancer
Current Pharmaceutical Design Impact of Alzheimers Disease on the Functional Connectivity of Spontaneous Brain Activity
Current Alzheimer Research Improving Cancer Chemotherapy with Modulators of ABC Drug Transporters
Current Drug Targets Review of Pediatric Osteoarticular Infections
Reviews on Recent Clinical Trials Anti-inflammatory Augmentation Therapy in Obsessive-compulsive Disorder: A Review
Letters in Drug Design & Discovery Retraction Notice: Current Management of Vomiting After Tonsillectomy in Children
Current Drug Safety Targeted Drug Delivery and Imaging Using Mobile Milli/Microrobots: A Promising Future Towards Theranostic Pharmaceutical Design
Current Pharmaceutical Design The Role of Co-Infections in Mother-to-Child Transmission of HIV
Current HIV Research Novel Rational Drug Design Strategies with Potential to Revolutionize Malaria Chemotherapy
Current Medicinal Chemistry Small Molecule Fluorescent Ligands as Central Nervous System Imaging Probes
Mini-Reviews in Medicinal Chemistry Physiologically-based Pharmacokinetic (PBPK) Modelling of Transporter Mediated Drug Absorption, Clearance and Drug-drug Interactions
Current Drug Metabolism Granulocyte Colony-stimulating Factor as the Expecting Sword for the Treatment of Severe Sepsis
Current Pharmaceutical Design Potential Role of (-)-Epigallocatechin-3-Gallate (EGCG) in the Secondary Prevention of Alzheimer Disease
Current Drug Targets Disorders of Respiration and Sleep-Disordered Breathing in Patients with Chronic Renal Failure
Current Respiratory Medicine Reviews Psoriasis in Children: A Review
Current Pediatric Reviews Inflammation and Chronic Oxidative Stress in Radiation-Induced Late Normal Tissue Injury: Therapeutic Implications
Current Medicinal Chemistry New Insights into the Mechanism of Action of Aspirin in the Prevention of Colorectal Neoplasia
Current Pharmaceutical Design